ABBV

AbbVie Inc. ABBV logo

NYSE Healthcare

$216.24

+3.25 (+1.52%)

Updated: 3/31/2026, 4:00:01 PM

Open

$215.06

High

$219.06

Low

$213.03

Prev Close

$213.12

Volume

2.30M

Price History

Why Is ABBV ▲ Up Today?

+1.52%

Full AI analysis generates after market close. Showing live price data.

Mar 31 ▲ +1.5% AbbVie (ABBV) Climbs on Analyst Support and Aesthetics Momentum

Mar 30 ▲ +1.8% AbbVie (ABBV) Rises Amidst Positive Dividend News and Sector Gains

Mar 27 ▼ -0.9% ABBV dips slightly amid sector weakness, remains attractive for dividends

Mar 26 ▲ +1.9% AbbVie (ABBV) Rises on Positive Catalysts, Pipeline Developments

Mar 25 ▲ +1.0% ABBV Rises Slightly Amidst Positive Sentiment and Sector Underperformance

Mar 24 ▲ +0.1% AbbVie (ABBV) Up Slightly Amidst Mixed Sentiment

Mar 23 ▼ -0.5% ABBV Declines Amidst Sector Weakness and Competitive Pressures

Mar 20 ▼ -0.6% ABBV Declines Amidst Sector Weakness and Competitive Pressure

Mar 19 ▼ -1.0% ABBV down 1.00% as competition heats up in immunology

Mar 18 ▼ -5.2% AbbVie (ABBV) Slides Amidst Healthcare Sector Weakness

Mar 17 ▼ -0.8% ABBV Declines Slightly Amid Sector Weakness

Mar 16 ▲ +0.7% AbbVie (ABBV) Up Slightly on Positive Obesity Drug Data

Mar 13 ▼ -2.5% AbbVie (ABBV) Drops Amidst Mixed Signals, Offsetting Positive News

Mar 12 ▼ -1.0% AbbVie (ABBV) dips slightly amid mixed signals, broader sector decline

Mar 11 ▲ +0.3% AbbVie (ABBV) modestly up on positive drug data

Mar 10 ▼ -0.2% AbbVie (ABBV) down slightly despite positive news

Mar 9 ▼ -1.0% AbbVie (ABBV) dips slightly despite positive drug data

Mar 6 ▼ -1.0% AbbVie (ABBV) Down Slightly Despite Positive News

Mar 5 ▼ -1.7% AbbVie (ABBV) dips slightly despite positive Skyrizi Crohn's data

Mar 4 ▲ +0.9% AbbVie (ABBV) Up Slightly on Positive Skyrizi Data, Manufacturing Expansion

Mar 3 ▼ -0.2% ABBV Down Slightly Despite Positive News

Mar 2 ▲ +0.9% AbbVie (ABBV) Climbs on Positive Crohn's Data, Outperforming Sector

Feb 27 ▲ +3.1% AbbVie (ABBV) Climbs on FDA Approval and Positive Outlook

Feb 26 ▼ -1.0% ABBV Declines Slightly Despite Positive News

Feb 25 ▼ -0.6% ABBV Down Slightly Despite Positive News; Market Weighs Valuation

Feb 24 ▼ -0.4% AbbVie (ABBV) dips slightly despite positive news

Feb 23 ▲ +2.1% AbbVie (ABBV) Climbs on FDA Approval, Dividend News

Feb 20 ▲ +0.2% AbbVie (ABBV) Up Slightly on FDA Approval, Dividend

Feb 19 ▼ -1.7% AbbVie (ABBV) dips amid mixed signals, declares dividend

Feb 18 ▼ -1.8% ABBV Declines Amidst Sector Weakness, Despite Strong Dividend

Highly Regarded Analysis

Updated Apr 10, 2026 • Refreshes daily

Rating

Highly Regarded

Risk

Medium

Target

$253.00

Type

Standard

Executive Summary

AbbVie is a research-based biopharmaceutical company with a strong portfolio in immunology, oncology, and aesthetics. It faces biosimilar competition for Humira but is growing through Skyrizi and Rinvoq, strategic acquisitions, and pipeline development. Analysts project continued revenue and EPS growth with a focus on immunology and neuroscience.

Bull Case

AbbVie's strengths lie in its diversified portfolio, strategic acquisitions (e.g., Capstan Therapeutics), and successful pipeline execution. Skyrizi and Rinvoq are expected to exceed peak Humira sales, driving revenue growth. The company's strong dividend yield provides valuation support.

Bear Case

AbbVie faces challenges from Humira biosimilars, potential pipeline setbacks, and competition in the aesthetics market. Patent cliffs in the 2030s and execution risks in oncology are also concerns.

Technical Outlook

The stock has shown rally potential and is currently near a support level, suggesting a potential buying opportunity.

Fundamental Health

AbbVie demonstrates a positive financial outlook, with strong sales growth in key products like Ubrelvy, Qulipta, and Botox Therapeutic. Management projects strong Neuroscience segment global sales growth.

Key Catalysts

Skyrizi and Rinvoq sales surpassing Humira
Neuroscience franchise growth
Strategic oncology acquisitions and pipeline development

Sources

morningstar.com public.com forbes.com seekingalpha.com finviz.com fool.com seekingalpha.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.